Jazz Pharmaceuticals, a Zacks Rank #1 (Strong Buy), is a specialty biopharmaceutical company that identifies, develops, and ...

HC Wainwright issued their Q1 2025 earnings estimates for shares of Jazz Pharmaceuticals in a research note issued to investors on Monday, March 10th. HC Wainwright analyst O. Livnat forecasts that ...

Chicago, IL – March 12, 2025 – Zacks Equity Research shares Jazz Pharmaceuticals JAZZ as the Bull of the Day and The Boston Beer Company SAM as the Bear ...

We maintain our fair value estimate of $187 per share. Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have continued to be Jazz’s primary ...

Jazz Pharmaceuticals acquires Chimerix (CMRX) for $935M, adding ONC201, a promising brain cancer drug. Find out why I believe ...

Limited or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' ...

Professor O’Sullivan’s presentation, “A Cannabidiol Cocrystal (ART12.11) Tablet Has Comparable Pharmacokinetics to Epidiolex,” highlighted results from canine studies evaluating Artelo’s ...

Although Epidiolex can cause adverse effects, including elevated liver enzymes, fatigue, and possible infections, investigators say that it is usually better tolerated than antipsychotic medications.

Professor O’Sullivan’s presentation, “A Cannabidiol Cocrystal (ART12.11) Tablet Has Comparable Pharmacokinetics to Epidiolex,” highlighted results from canine studies evaluating Artelo’s oral solid ...

It is one of the best cash rich stocks to invest in. On December 6, 2024, the company shared new research on Epidiolex ...

Jazz Pharmaceuticals PLC (JAZZ) achieves record-breaking revenue in 2024, outlines strategic growth initiatives for 2025 amidst competitive challenges.